{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T09:02:58Z","timestamp":1780304578899,"version":"3.54.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revista Cl\u00ednica Espa\u00f1ola (English Edition)"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.rceng.2026.502562","type":"journal-article","created":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T07:13:44Z","timestamp":1777360424000},"page":"502562","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world impact of oral semaglutide on inflammatory markers in patients at high cardiovascular risk"],"prefix":"10.1016","volume":"226","author":[{"given":"S.","family":"Mariscal V\u00e1zquez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Jim\u00e9nez-M\u00e9ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"P\u00e9rez Asensio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etelino","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Rodr\u00edguez Delgado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Garc\u00eda Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"del Rocio Bulo Concell\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.A.","family":"Panera de la Mano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Garrido Vital","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Calle P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rceng.2026.502562_bib0005","series-title":"Global status report on noncommunicable diseases 2023","year":"2023"},{"key":"10.1016\/j.rceng.2026.502562_bib0010","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1056\/NEJMra043430","article-title":"Inflammation, atherosclerosis, and coronary artery disease","volume":"352","author":"Hansson","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rceng.2026.502562_bib0015","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1161\/01.CIR.0000052939.59093.45","article-title":"Markers of inflammation and cardiovascular disease: application to clinical and public health practice","volume":"107","author":"Pearson","year":"2003","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.rceng.2026.502562_bib0020","first-page":"403","article-title":"High-sensitivity C-reactive protein as a predictor of cardiovascular disease","volume":"55","author":"Ridker","year":"2009","journal-title":"Clin Chem"},{"key":"10.1016\/j.rceng.2026.502562_bib0025","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1056\/NEJMoa1107477","article-title":"C-reactive protein, fibrinogen, and cardiovascular disease prediction","volume":"367","author":"Kaptoge","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rceng.2026.502562_bib0030","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1001\/jama.286.3.327","article-title":"C-reactive protein, interleukin-6, and risk of developing type 2 diabetes mellitus","volume":"286","author":"Pradhan","year":"2001","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.rceng.2026.502562_bib0035","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1161\/CIRCRESAHA.116.308537","article-title":"Pleiotropic effects of statins on the cardiovascular system","volume":"120","author":"Oesterle","year":"2017","journal-title":"Circ Res"},{"issue":"27","key":"10.1016\/j.rceng.2026.502562_bib0040","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1093\/eurheartj\/ehu203","article-title":"Anti-inflammatory therapies for cardiovascular disease","volume":"35","author":"Ridker","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.rceng.2026.502562_bib0045","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.cmet.2018.03.001","article-title":"Mechanisms of action and therapeutic application of glucagon-like peptide-1","volume":"27","author":"Drucker","year":"2018","journal-title":"Cell Metab"},{"key":"10.1016\/j.rceng.2026.502562_bib0050","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/3094642","article-title":"Anti-inflammatory effects of GLP-1-based therapies beyond glucose control","volume":"2016","author":"Lee","year":"2016","journal-title":"Mediators Inflamm"},{"key":"10.1016\/j.rceng.2026.502562_bib0055","first-page":"607","article-title":"The GLP-1 analogue liraglutide reduces atherosclerosis in ApoE\u2212\/\u2212 and LDLr\u2212\/\u2212 mice through a mechanism involving inflammatory pathways","volume":"53","author":"Rakipovski","year":"2010","journal-title":"Diabetologia"},{"key":"10.1016\/j.rceng.2026.502562_bib0060","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1093\/eurheartj\/ehz486","article-title":"2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD","volume":"41","author":"Cosentino","year":"2020","journal-title":"Eur Heart J"},{"issue":"Suppl. 1","key":"10.1016\/j.rceng.2026.502562_bib0065","first-page":"S1","article-title":"Standards of care in diabetes\u20142024","volume":"47","author":"Bahiru","year":"2024","journal-title":"Diabetes Care"},{"key":"10.1016\/j.rceng.2026.502562_bib0070","series-title":"Rybelsus\u00ae (semaglutide) summary of product characteristics","year":"2024"},{"issue":"6","key":"10.1016\/j.rceng.2026.502562_bib0075","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.jacc.2015.11.037","article-title":"A test in context: high-sensitivity C-reactive protein","volume":"67","author":"Ridker","year":"2016","journal-title":"J Am Coll Cardiol"},{"issue":"10118","key":"10.1016\/j.rceng.2026.502562_bib0080","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0140-6736(17)32814-3","article-title":"Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomized controlled trial","volume":"391","author":"Ridker","year":"2018","journal-title":"Lancet"},{"issue":"14","key":"10.1016\/j.rceng.2026.502562_bib0085","first-page":"1799","article-title":"Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis","volume":"294","author":"Danesh","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.rceng.2026.502562_bib0090","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/nature01323","article-title":"Inflammation in atherosclerosis","volume":"420","author":"Libby","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.rceng.2026.502562_bib0095","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated high-sensitivity C-reactive protein (JUPITER)","volume":"359","author":"Ridker","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rceng.2026.502562_bib0100","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1056\/NEJMoa1912388","article-title":"Efficacy and safety of low-dose colchicine after myocardial infarction (COLCOT)","volume":"381","author":"Tardif","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rceng.2026.502562_bib0105","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1056\/NEJMoa2021372","article-title":"Colchicine in patients with chronic coronary disease (LoDoCo2)","volume":"383","author":"Nidorf","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rceng.2026.502562_bib0110","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Anti-inflammatory therapy with canakinumab for atherosclerotic disease (CANTOS)","volume":"377","author":"Ridker","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rceng.2026.502562_bib0115","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1093\/qjmed\/hcg129","article-title":"Fibrinogen: biochemistry, epidemiology, and determinants","volume":"96","author":"Kamath","year":"2003","journal-title":"QJM"},{"key":"10.1016\/j.rceng.2026.502562_bib0120","doi-asserted-by":"crossref","first-page":"956","DOI":"10.7326\/0003-4819-118-12-199306150-00008","article-title":"Fibrinogen as a cardiovascular risk factor: a meta-analysis and review of the literature","volume":"118","author":"Ernst","year":"1993","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.rceng.2026.502562_bib0125","first-page":"1","article-title":"Enhanced antigen presentation by macrophages promotes human atherosclerosis progression: therapeutic implications","volume":"00","author":"Xie","year":"2025","journal-title":"Eur Heart J"},{"issue":"22","key":"10.1016\/j.rceng.2026.502562_bib0130","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1093\/eurheartj\/ehw024","article-title":"Residual inflammatory risk: addressing the other side of the atherosclerosis prevention coin","volume":"37","author":"Ridker","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.rceng.2026.502562_bib0135","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1016\/S0140-6736(06)69705-5","article-title":"The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes","volume":"368","author":"Drucker","year":"2006","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.rceng.2026.502562_bib0140","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.rce.2022.11.007","article-title":"Ar\u00e9valo-Lorido JC; Effect of semaglutide on fatty liver disease biomarkers in patients with diabetes and obesity","volume":"223","author":"Carretero-G\u00f3mez","year":"2023","journal-title":"Rev Clin Esp (Barc)"},{"key":"10.1016\/j.rceng.2026.502562_bib0145","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes (SUSTAIN-6)","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rceng.2026.502562_bib0150","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1056\/NEJMoa1901118","article-title":"Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes (PIONEER 6)","volume":"381","author":"Husain","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rceng.2026.502562_bib0155","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity (STEP 1)","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.rceng.2026.502562_bib0160","first-page":"327","article-title":"Effects of semaglutide on inflammatory markers: a systematic review and meta-analysis","volume":"25","author":"Cao","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.rceng.2026.502562_bib0165","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.2337\/dc19-0749","article-title":"Efficacy and safety of oral semaglutide monotherapy in type 2 diabetes (PIONEER 1)","volume":"42","author":"Ahmann","year":"2019","journal-title":"Diabetes Care"},{"key":"10.1016\/j.rceng.2026.502562_bib0170","first-page":"1803","article-title":"Efficacy and safety of oral semaglutide added to insulin and metformin in patients with type 2 diabetes (PIONEER 8)","volume":"43","author":"Davies","year":"2020","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.rceng.2026.502562_bib0175","first-page":"297","article-title":"Oral semaglutide: overview of safety and tolerability data","volume":"20","author":"Ahmann","year":"2021","journal-title":"Expert Opin Drug Saf"},{"issue":"7","key":"10.1016\/j.rceng.2026.502562_bib0180","first-page":"616","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rceng.2026.502562_bib0185","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND)","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.rceng.2026.502562_bib0190","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes (LEADER)","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"}],"container-title":["Revista Cl\u00ednica Espa\u00f1ola (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2254887426000913?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2254887426000913?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T08:10:18Z","timestamp":1780301418000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2254887426000913"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":38,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S2254887426000913"],"URL":"https:\/\/doi.org\/10.1016\/j.rceng.2026.502562","relation":{},"ISSN":["2254-8874"],"issn-type":[{"value":"2254-8874","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world impact of oral semaglutide on inflammatory markers in patients at high cardiovascular risk","name":"articletitle","label":"Article Title"},{"value":"Revista Cl\u00ednica Espa\u00f1ola (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rceng.2026.502562","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.rce.2026.502562","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Espa\u00f1a, S.L.U. and Sociedad Espa\u00f1ola de Medicina Interna (SEMI). All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"502562"}}